Thelansis

  Benign essential blepharospasm (BEB) is a rare neurological disorder characterised by involuntary muscle spasms and contractions of the muscles around the eyes. Approximately 2,000 new cases of BEB are diagnosed in the United States each year. BEB affects around 5 out of every 1,00,000 people in the general population. Thelansis’s “Benign Essential Blepharospasm (BEB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Benign Essential Blepharospasm (BEB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Benign Essential Blepharospasm (BEB) across 8 MM market from the centre of Excellence/ Public/ Pri...